The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): 29-month (mo) follow-up from CheckMate 648.
 
Ken Kato
Honoraria - BMS; Lilly; Ono Pharmaceutical
Consulting or Advisory Role - Bayer; BeiGene; MSD; Oncolys BioPharma; Ono Pharmaceutical
Speakers' Bureau - Bristol-Myers Squibb Japan; MSD; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Bayer (Inst); Beigene (Inst); Chugai Pharma (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst)
 
Jaffer A. Ajani
Honoraria - Acrotech Biopharma; Aduro Biotech; Amgen; Astellas Pharma; AstraZeneca; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; DAVA Pharmaceuticals; Fresenius Kabi; Gilead Sciences; GRAIL; Lilly; Merck; Novartis; oncotherics; SERVIER; zymeworks
Consulting or Advisory Role - American Cancer Society; Amgen; Arcus Biosciences; Astellas Pharma; BeiGene; BeiGene; Bristol-Myers Squibb; Geneos; Gilead Sciences; Insys Therapeutics; Merck; Novartis; SERVIER; Vaccinogen
Research Funding - Amgen; Astellas Pharma (Inst); Bristol-Myers Squibb; Daiichi Sankyo; Delta-Fly Pharma; Gilead Sciences; Lilly/ImClone; Merck; Novartis; ProLynx; Roche/Genentech; Taiho Pharmaceutical; Takeda; Zymeworks
Patents, Royalties, Other Intellectual Property - I have research funding from: Genentech, Roche, BMS, Taiho, MedImmune, Merck, Amgen, Lilly
 
Yuichiro Doki
Honoraria - Chugai Pharma; Daiichi Sankyo; Lilly Japan; MSD; Ono Pharmaceutical; Otsuka; Taiho Pharmaceutical
Consulting or Advisory Role - Ono Pharmaceutical
Research Funding - Chugai Pharma; Daiichi Sankyo; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
 
Jianming Xu
No Relationships to Disclose
 
Lucjan Wyrwicz
Honoraria - BeiGene; BMS; MSD
Consulting or Advisory Role - GlaxoSmithKline; SERVIER
Speakers' Bureau - BMS
Travel, Accommodations, Expenses - SERVIER
 
Satoru Motoyama
No Relationships to Disclose
 
Takashi Ogata
Speakers' Bureau - Bristol Myers Squibb Foundation; MSD; Ono Pharmaceutical
 
Hisato Kawakami
Honoraria - Bayer; Bristol-Myers Squibb Japan; Chugai/Roche; Daiichi Sankyo; Lilly Japan; Merck Serono; MSD K.K; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical
Consulting or Advisory Role - Bristol-Myers Squibb Japan; Daiichi Sankyo Co. Ltd.,; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Kobayashi Pharmaceutical (Inst)
 
Chih-Hung Hsu
Honoraria - Bristol-Myers Squibb; Eisai; Merck Sharp & Dohme; Ono Pharmaceutical; Roche
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Serono; MSD; Ono Pharmaceutical; Roche/Genentech
Research Funding - AstraZeneca (Inst); BeiGene (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Eucure Biopharma (Inst); Johnson & Johnson (Inst); Merck Serono (Inst); MSD (Inst); NGM Biopharmaceuticals (Inst); Nucana (Inst); Ono Pharmaceutical (Inst); Roche/Genentech (Inst); Taiho Pharmaceutical (Inst)
 
Antoine Adenis
Consulting or Advisory Role - Arcus Biosciences; Astellas Pharma; Bayer Health; Bristol-Myers Squibb; Merck; Merck Serono
Speakers' Bureau - Bristol-Myers Squibb; MSD Oncology; Novartis
Research Funding - Arcus Ventures (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Roche (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD; Pierre Fabre; SERVIER
 
Farid El Hajbi
No Relationships to Disclose
 
Maria Di Bartolomeo
Honoraria - BMSi; Lilly; MSD Oncology; SERVIER
Consulting or Advisory Role - Lilly; MSD Oncology
Research Funding - Lilly (Inst)
Travel, Accommodations, Expenses - Daiichi Sankyo/Astra Zeneca
 
Maria Ignez Freitas Melro Braghiroli
Honoraria - Amgen; BMS Brazil; Eurofarma; MSD; Takeda
Consulting or Advisory Role - Lilly; Merck; MSD; Roche; SERVIER; SERVIER
Travel, Accommodations, Expenses - MSD
 
Eva Holtved
No Relationships to Disclose
 
Mariela A. Blum Murphy
Research Funding - Bristol-Myers Squibb (Inst); Genentech/Roche (Inst)
 
Apurva Patel
Employment - Bristol Myers Squibb
Stock and Other Ownership Interests - Bristol Myers Squibb; Merck
 
Nan Hu
Employment - Bristol-Myers Squibb
 
Yasuhiro Matsumura
Employment - Ono Pharmaceutical
Stock and Other Ownership Interests - Ono Pharmaceutical
 
Ian Chau
Honoraria - Eisai; Lilly; Roche/Genentech; SERVIER
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Eisai; GlaxoSmithKline; Incyte; Lilly; Merck Serono; MSD Oncology; OncXerna Therapeutics; Roche/Genentech; Seagen; SERVIER; Sotio; Taiho Oncology; Turning Point Therapeutics
Research Funding - Janssen-Cilag (Inst); Lilly (Inst)
 
Yuko Kitagawa
Honoraria - Asahi Kasei; AstraZeneca Japan; Bristol-Myers Squibb K.K.; Chugai Pharma; Ethicon; Kaken Pharmaceutical; MSD K.K.; Nippon Covidien; Olympus; Ono Pharmaceutical; Otsuka; Shionogi; Smith & Nephew; Taiho Pharmaceutical
Consulting or Advisory Role - Bristol-Myers Squibb K.K.; Ono Pharmaceutical
Research Funding - Asahi Kasei (Inst); Chugai Pharma (Inst); EA Pharma (Inst); Eisai (Inst); Kaken Pharmaceutical (Inst); Kyouwa Hakkou Kirin Co., Ltd. (Inst); Medicon (Inst); Nihon Pharma (Inst); Nippon Covidien (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Otsuka (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Teijin Pharma (Inst); TSUMURA & CO. (Inst); Yakult Honsha (Inst)